CPT 64581, in plain terms, covers A surgeon makes an incision to surgically place a device that stimulates nerves near the tailbone area. CPT 64581 is referenced in 19 tracked payer policy changes from Harvard Pilgrim Health Care, Humana, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 64581 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 64581 on AAPC
Point32Health (Harvard Pilgrim/Tufts) is implementing multiple Medical Necessity Guideline updates with new prior authorization requirements for various procedures including foot reconstruction, gender affirming services, therapeutic apheresis, and Medicare-covered services. Additionally, some existing procedures like esophageal dilation will now require appropriate ICD-10 codes for coverage without prior auth.
Effective January 1, 2026, Harvard Pilgrim Health Care Commercial plans will deny claims for specific procedure codes unless proper diagnosis codes are also submitted. Claims for procedure codes 64561, 64581, or A4290 require a diagnosis of urinary or fecal incontinence, and ambulatory blood pressure monitoring codes (93784-93790) require elevated blood pressure without hypertension diagnosis.
This is a historical policy document (discovered 2026-11-03, but issue dated 2026-10-01 with effective date 2026-10-01) that consolidates Humana Medicare Advantage coverage criteria for nerve stimulation procedures treating urinary incontinence, including sacral nerve stimulation (SNS), percutaneous posterior tibial nerve stimulation (PTNS), and implanted PTNS. The policy references applicable MAC LCDs by geographic jurisdiction and establishes medical necessity criteria for device placement, removal, and replacement across all covered procedures.
This is a revised Medicare Advantage policy on nerve stimulation for urinary incontinence effective October 1, 2026. The policy establishes coverage criteria for sacral nerve stimulation (SNS), percutaneous posterior tibial nerve stimulation (PTNS), and implanted PTNS procedures, with specific medical necessity requirements for device placement, removal, and replacement across all Humana Medicare Advantage jurisdictions.
Humana Medicare Advantage updated coverage criteria for nerve stimulation procedures treating urinary incontinence, including sacral nerve stimulation and posterior tibial nerve stimulation. The policy establishes specific medical necessity criteria for implantation, removal, and replacement of these devices.
Excellus BlueCross BlueShield policy 7.01.10, Sacral Nerve Stimulation, has a current effective date of March 16, 2026. The November 20, 2025 off-cycle review clarified the sacral nerve stimulation trial and permanent placement criteria. Sacral nerve stimulation is medically appropriate for individuals 16 and older who meet both the trial stimulation and permanent placement criteria, and it is considered investigational for stress incontinence, urge incontinence due to a neurological condition, other chronic voiding dysfunction, constipation, chronic pelvic pain and bilateral sacral nerve stimulation.
Independence Blue Cross reissued Policy 11.17.04z to add two new CPT codes (0988T and 0989T) as experimental/investigational effective 01/01/2026. These codes are excluded from coverage for all Independence Blue Cross products and are not eligible for reimbursement. The policy also reaffirms existing coverage criteria for sacral nerve stimulation (SNS) and posterior tibial nerve stimulation (PTNS) for incontinence treatment.
Humana Medicare Advantage updated their nerve stimulation policy for fecal incontinence, covering sacral nerve stimulation procedures but explicitly excluding percutaneous tibial nerve stimulation as not medically necessary. The policy establishes specific criteria for device removal and replacement procedures.
Aetna considers cannabinoids, hypnotherapy, hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis, neuromodulation (dorsal root ganglion stimulation, posterior tibial nerve stimulation, sacral nerve stimulation, and spinal cord stimulation), peritoneal excision (stripping) for endometriosis, and superior hypogastric plexus block with traditional pharmacological treatments experimental, investigational, or unproven. Uterine nerve ablation, laparoscopic uterine nerve ablation and presacral neurectomy are also considered experimental, investigational, or unproven for chronic pelvic pain or other indications. The policy lists related CPT and HCPCS codes, and endometriosis ICD-10 codes, as not covered for the indications it names.
Policy A.7.01.69 states that sacral nerve neuromodulation may be considered medically necessary as a trial for urge incontinence, urgency-frequency syndrome, non-obstructive urinary retention, or overactive bladder when the listed criteria are met, and as a trial for chronic fecal incontinence when its separate criteria are met. Permanent implantation may be considered medically necessary when those criteria are met and a trial stimulation period shows at least 50% improvement in symptoms over at least 48 hours, while chronic constipation, chronic pelvic pain, stress incontinence, and urge incontinence due to a neurologic condition are investigational. The policy was updated on 09/17/2026 to change the device description, renumber the urinary incontinence Criteria A statements, and remove ICD-9 procedure and diagnosis codes from the code reference section.
Aetna considers TENS units medically necessary durable medical equipment when used as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic, intractable pain not adequately responsive to other methods. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when all listed criteria are met. Percutaneous electrical nerve stimulation is considered medically necessary for chronic low back pain secondary to degenerative disc disease for up to a 30-day period within a multi-modality rehabilitation program, and for diabetic neuropathy or neuropathic pain that has not responded to listed medications. Many other electrical stimulation devices and indications are listed as experimental, investigational, or unproven.
Aetna's Clinical Policy Bulletin 0611 covers fecal incontinence. It considers anorectal manometry, anorectal ultrasonography, rectal sensory testing, biofeedback, bowel training, defecation programs, diet modification and pharmacotherapy medically necessary, and it lists anal sphincter repair, colostomy, the Acticon Neosphincter and sacral nerve stimulation as invasive treatments that need all diagnostic tests and a 3-month trial of two or more traditional treatments first, unless contraindicated. Several other treatments are listed as experimental, investigational or unproven, including anal slings, graciloplasty, injectable bulking agents, magnetic anal sphincter augmentation, posterior tibial nerve stimulation, topical estrogen, topical oxymetazoline, trans-anal radiofrequency therapy (Secca) and vaginal bowel control (Eclipse system).
Aetna considers physical therapy, perineoplasty, and vestibulectomy (local or total) medically necessary for vulvodynia and vulvar vestibulitis. Vestibulectomy is considered medically necessary for persons who have failed conservative measures (including vulvar care, physical therapy, and pharmacotherapy including analgesics) and who have had a musculoskeletal evaluation that ruled out factors such as pelvic muscle over-activity and myofascial or other biomechanical disorders, or a 3-month trial and failure of treatments for those disorders. Acupuncture, botulinum toxin, laser therapy, sacral neuromodulation, spinal cord stimulation, TENS, hypnotherapy, and many other listed treatments are considered experimental, investigational, or unproven for this indication because their effectiveness has not been established.
Aetna Clinical Policy Bulletin 0223 on urinary incontinence, reviewed 2026-07-16, considers multi-channel urodynamic studies medically necessary when a member has both symptoms and physical findings of urinary incontinence or voiding dysfunction and the provider is considering invasive, potentially morbid or irreversible treatment after conservative management has failed. It considers medically necessary the artificial urinary sphincter, FDA-cleared peri-urethral bulking agents, permanent sacral nerve stimulators after temporary trial stimulation, percutaneous tibial nerve stimulation, weighted vaginal cones, pessaries, tension-free and transobturator tape procedures, colposuspension and sub-urethral sling procedures when the stated criteria are met. Bilateral permanent sacral nerve stimulator implantation, the Genityte and FemiLift laser procedures, stem cell therapy and many other listed interventions are considered experimental, investigational or unproven.
Aetna covers sacral nerve stimulation for members with chronic fecal incontinence who have had an inadequate response to conservative treatment and have a weak but structurally intact anal sphincter. A temporary percutaneous peripheral nerve electrode is tested first, and a permanent implantable pulse generator is medically necessary only for members who have a 50% or greater improvement in incontinence symptoms from the temporary stimulation over a period of at least 48 hours. Anal sphincter repair, colostomy and the Acticon Neosphincter artificial bowel sphincter are medically necessary for severe fecal incontinence, defined as involuntary loss of solid or liquid stool on a weekly or more frequent basis, after all diagnostic tests and a 3-month trial of 2 or more traditional treatments, unless contraindicated, and after failure of or inability to use medical interventions. Anal slings, graciloplasty, injectable bulking agents, transanal radiofrequency therapy (Secca procedure), posterior tibial nerve stimulation, topical estrogen and several other listed treatments are considered experimental, investigational or unproven.
Cannabinoids, hypnotherapy, hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis, neuromodulation (dorsal root ganglion stimulation, posterior tibial nerve stimulation, sacral nerve stimulation, and spinal cord stimulation), peritoneal excision (stripping) for endometriosis, superior hypogastric plexus block with traditional pharmacological treatments, and uterine nerve ablation, laparoscopic uterine nerve ablation and presacral neurectomy for chronic pelvic pain or other indications are considered experimental, investigational, or unproven because their effectiveness has not been established. The policy lists CPT codes not covered for the indications it lists, including neurostimulator implantation, revision, removal and programming codes, superior hypogastric plexus injection code 64517, and hypnotherapy code 90880, along with ICD-10 diagnosis codes not covered for those indications. Peritoneal excision (stripping) has no specific code in this policy.
Aetna considers embolization of gonadal or ovarian veins, with or without the internal iliac veins, medically necessary for pelvic congestion syndrome when the member has had a definitive diagnostic venography, CT or MRI and has failed a trial of appropriate pharmacotherapy such as analgesics or hormonal therapy. Gonadal or ovarian vein embolization for pelvic congestion syndrome is experimental, investigational, or unproven when those criteria are not met. Median sacral vein embolization for pelvic congestion syndrome, ovarian vein transposition, sacral nerve root neuromodulation for chronic pelvic pain, and micronized purified flavonoid fraction for pelvic congestion syndrome are listed as experimental, investigational, or unproven.
A trial of sacral nerve neuromodulation, using percutaneous nerve stimulation or a temporarily implanted lead, may be considered medically necessary for urge incontinence, urgency-frequency syndrome, non-obstructive urinary retention, or overactive bladder when the listed criteria are met. Permanent implantation may be considered medically necessary when those criteria are met and a trial stimulation period demonstrates at least 50% improvement in symptoms over at least 48 hours. For chronic fecal incontinence, a trial may be considered for more than 2 incontinent episodes on average per week for more than 6 months, or more than 12 months after vaginal childbirth, after documented failure of conventional conservative therapy. Sacral nerve neuromodulation is considered investigational for chronic constipation, chronic pelvic pain, stress incontinence, and urge incontinence due to a neurologic condition. The 09/17/2026 update revised device descriptions, re-numbered the Criteria A statements for urinary incontinence, and removed ICD-9 procedure and diagnosis codes from the code reference.
Independence Blue Cross reissued MA11.028l on 01/21/2026 to communicate the company's continuing position on Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS) for incontinence control. Two new experimental/investigational CPT codes (0988T and 0989T) were added effective 01/01/2026 and are NOT covered. No changes to existing coverage criteria or medically necessary procedures.
Watch 64581
Get one email when a payer policy names 64581, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 64581
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 64581 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.